The USFDA has approved navepegritide, a C-type natriuretic peptide (CNP) analog, to increase linear growth in pediatric patients aged 2 years and older with achondroplasia who have open epiphyses. Clinical evidence In a clinical trial involving 84 children with achondroplasia, navepegritide significantly improved annualized growth velocity versus placebo (5.9 vs 4.4 cm/year) and increased height Z-scores, with consistent benefits across subgroups.
Dosage and administration Available as subcutaneous injection Administer once-weekly by subcutaneous injection Dosage is based on body weight Periodically monitor growth and adjust dose according to body weight. Discontinue when no further growth potential, as indicated by epiphyseal closure Contraindications None Warnings and precautions Risk of low blood pressure Adverse reactions Vomiting, Injection-site reaction, Pain in extremity Nausea…
